{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:57:34Z","timestamp":1792634254754,"version":"4.5.0"},"reference-count":126,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T00:00:00Z","timestamp":1629244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cancer cells utilise several mechanisms to increase their survival and progression as well as their resistance to anticancer therapy: deregulation of growth regulatory pathways by acquiring grow factor independence, immune system suppression, reducing the expression of antigens activating T lymphocyte cells (mimicry), induction of anti-apoptotic signals to counter the action of drugs, activation of several DNA repair mechanisms and driving the active efflux of drugs from the cell cytoplasm, and epigenetic regulation by microRNAs (miRNAs). Because it is commonly diagnosed late, lung cancer remains a major malignancy with a low five-year survival rate; when diagnosed, the cancer is often highly advanced, and the cancer cells may have acquired drug resistance. This review summarises the main mechanisms involved in cisplatin resistance and interactions between cisplatin-resistant cancer cells and the tumour microenvironment. It also analyses changes in the gene expression profile of cisplatin sensitive vs. cisplatin-resistant non-small cell lung cancer (NSCLC) cellular model using the GSE108214 Gene Expression Omnibus database. It describes a protein-protein interaction network that indicates highly dysregulated TP53, MDM2, and CDKN1A genes as they encode the top networking proteins that may be involved in cisplatin tolerance, these all being upregulated in cisplatin-resistant cells. Furthermore, it illustrates the multifactorial nature of cisplatin resistance by examining the diversity of dysregulated pathways present in cisplatin-resistant NSCLC cells based on KEGG pathway analysis.<\/jats:p>","DOI":"10.3390\/ijms22168885","type":"journal-article","created":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T10:54:35Z","timestamp":1629284075000},"page":"8885","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":175,"title":["Molecular Mechanisms of Chemoresistance Induced by Cisplatin in NSCLC Cancer Therapy"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7342-7342","authenticated-orcid":false,"given":"Jolanta","family":"Kryczka","sequence":"first","affiliation":[{"name":"Department of Biomedicine and Genetics, Medical University of Lodz, 92-213 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5719-4139","authenticated-orcid":false,"given":"Jakub","family":"Kryczka","sequence":"additional","affiliation":[{"name":"Institute of Medical Biology, Polish Academy of Sciences, 93-232 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4013-513X","authenticated-orcid":false,"given":"Karolina H.","family":"Czarnecka-Chrebelska","sequence":"additional","affiliation":[{"name":"Department of Biomedicine and Genetics, Medical University of Lodz, 92-213 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0882-1458","authenticated-orcid":false,"given":"Ewa","family":"Brzezia\u0144ska-Lasota","sequence":"additional","affiliation":[{"name":"Department of Biomedicine and Genetics, Medical University of Lodz, 92-213 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00280-019-03902-6","article-title":"Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer","volume":"84","author":"Roys","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Kryczka, J., Migdalska-S\u0119k, M., Kordiak, J., Kisza\u0142kiewicz, J.M., Pastuszak-Lewandoska, D., Antczak, A., and Brzezia\u0144ska-Lasota, E. (2021). Serum Extracellular Vesicle-Derived miRNAs in Patients with Non-Small Cell Lung Cancer\u2014Search for Non-Invasive Diagnostic Biomarkers. Diagnostics, 11.","DOI":"10.3390\/diagnostics11030425"},{"key":"ref_3","unstructured":"(2020, January 15). Cancer Today. Available online: http:\/\/gco.iarc.fr\/today\/home."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"170070","DOI":"10.1098\/rsob.170070","article-title":"Progress and prospects of early detection in lung cancer","volume":"7","author":"Crosbie","year":"2017","journal-title":"Open Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"725","DOI":"10.17219\/acem\/68631","article-title":"Multiple primary lung cancer: A literature review","volume":"27","author":"Romaszko","year":"2018","journal-title":"Adv. Clin. Exp. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015 world health organization classification of lung tumors: Impact of genetic, clinical and radiologic advances Since the 2004 classification","volume":"10","author":"Travis","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"709","DOI":"10.21037\/qims.2018.08.02","article-title":"The 8th lung cancer TNM classification and clinical staging system: Review of the changes and clinical implications","volume":"8","author":"Lim","year":"2018","journal-title":"Quant. Imaging Med. Surg."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.semcancer.2017.11.019","article-title":"Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC). Moving from targeted therapy to immunotherapy","volume":"52","author":"Osmani","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"288","DOI":"10.21037\/tlcr.2016.06.07","article-title":"Non-small cell lung cancer: Current treatment and future advances","volume":"5","author":"Zappa","year":"2016","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0033-8389(05)70176-7","article-title":"Epidemiology of lung cancer","volume":"38","author":"Smith","year":"2000","journal-title":"Radiol. Clin. N. Am."},{"key":"ref_11","first-page":"CD010383","article-title":"First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer","volume":"25","author":"Greenhalgh","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_12","unstructured":"(2021, August 12). Non-Small Cell Lung Cancer Treatment (PDQ\u00ae)\u2013Health Professional Version. National Cancer Institute, Available online: https:\/\/www.cancer.gov\/types\/lung\/hp\/non-small-cell-lung-treatment-pdq."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e201367","DOI":"10.4061\/2010\/201367","article-title":"Cellular responses to cisplatin-induced DNA damage","volume":"2010","author":"Basu","year":"2010","journal-title":"J. Nucleic Acids"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1042\/CBI20110329","article-title":"Cisplatin resistance induced by decreased apoptotic activity in non-small-cell lung cancer cell lines","volume":"36","author":"Cetintas","year":"2012","journal-title":"Cell Biol. Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3747\/co.19.1113","article-title":"Drug resistance and its significance for treatment decisions in non-small-cell lung cancer","volume":"19","author":"Goss","year":"2012","journal-title":"Curr. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Sarin, N., Engel, F., Kalayda, G.V., Mannewitz, M., Cinatl, J., Rothweiler, F., Michaelis, M., Saafan, H., Ritter, C.A., and Jaehde, U. (2017). Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2\/M cell cycle arrest. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0181081"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e1257","DOI":"10.1038\/cddis.2013.428","article-title":"Systems biology of cisplatin resistance: Past, present and future","volume":"5","author":"Galluzzi","year":"2014","journal-title":"Cell Death Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1021\/cr040704h","article-title":"Interactions of antitumor metallodrugs with serum proteins: Advances in characterization using modern analytical methodology","volume":"106","author":"Timerbaev","year":"2006","journal-title":"Chem. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1042\/bj3060771","article-title":"Nitrone spin traps and a nitroxide antioxidant inhibit a common pathway of thymocyte apoptosis","volume":"306","author":"Slater","year":"1995","journal-title":"Biochem. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1248\/bpb.28.707","article-title":"Expression of multidrug resistance proteins and accumulation of cisplatin in human non-small cell lung cancer cells","volume":"28","author":"Ikuta","year":"2005","journal-title":"Biol. Pharm. Bull."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: Molecular mechanisms of action","volume":"740","author":"Dasari","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0169-5002(02)00224-6","article-title":"DNA repair and cisplatin resistance in non-small-cell lung cancer","volume":"38","author":"Rosell","year":"2002","journal-title":"Lung Cancer"},{"key":"ref_23","unstructured":"Alison, M.R. (2005). Mechanisms of action of cancer chemotherapeutic agents: DNA-interactive alkylating agents and antitumour platinum-based drugs. The Cancer Handbook, John Wiley & Sons Ltd."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Kryczka, J., and Boncela, J. (2018). Cell migration related to MDR\u2014Another impediment to effective chemotherapy?. Molecules, 23.","DOI":"10.3390\/molecules23020331"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3389\/fonc.2018.00267","article-title":"Drug resistance in non-small cell lung cancer: A potential for NOTCH targeting?","volume":"8","author":"Giuranno","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1016\/S0169-5002(01)00355-5","article-title":"Drug resistance in non-small cell lung cancer","volume":"34","author":"Monzo","year":"2001","journal-title":"Lung Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"115754","DOI":"10.18632\/oncotarget.22975","article-title":"MicroRNAs as regulators of cisplatin-resistance in non-small cell lung carcinomas","volume":"8","author":"Fadejeva","year":"2017","journal-title":"Oncotarget"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ctrv.2016.05.004","article-title":"Can the response to a platinum-based therapy be predicted by the DNA repair status in non-small cell lung cancer?","volume":"48","author":"Macerelli","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1021\/cr980421n","article-title":"Structure, recognition, and processing of cisplatin-DNA adducts","volume":"99","author":"Jamieson","year":"1999","journal-title":"Chem. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.mrrev.2014.11.005","article-title":"Crosstalk between translesion synthesis, Fanconi anemia network, and homologous recombination repair pathways in interstrand DNA crosslink repair and development of chemoresistance","volume":"763","author":"Haynes","year":"2015","journal-title":"Mutat. Res. Rev. Mutat. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1200\/JCO.2000.18.19.3390","article-title":"Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer","volume":"18","author":"Gatzemeier","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/em.20573","article-title":"Translesion DNA synthesis polymerases in DNA interstrand crosslink repair","volume":"51","author":"Ho","year":"2010","journal-title":"Environ. Mol. Mutagenesis"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s13402-016-0291-7","article-title":"The functional status of DNA repair pathways determines the sensitization effect to cisplatin in non-small cell lung cancer cells","volume":"39","author":"Chen","year":"2016","journal-title":"Cell Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/09674845.2013.11669927","article-title":"DNA damage repair and tolerance: A role in chemotherapeutic drug resistance","volume":"70","author":"Salehan","year":"2013","journal-title":"Br. J. Biomed. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"18107","DOI":"10.1073\/pnas.0608595103","article-title":"Human SHPRH is a ubiquitin ligase for Mms2\u2013Ubc13-dependent polyubiquitylation of proliferating cell nuclear antigen","volume":"103","author":"Unk","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"10394","DOI":"10.1093\/nar\/gks763","article-title":"En bloc transfer of polyubiquitin chains to PCNA in vitro is mediated by two different human E2-E3 pairs","volume":"40","author":"Masuda","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"12455","DOI":"10.1073\/pnas.1206052109","article-title":"Pol31 and Pol32 subunits of yeast DNA polymerase \u03b4 are also essential subunits of DNA polymerase \u03b6","volume":"109","author":"Johnson","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1038\/aps.2016.100","article-title":"RAD18 polymorphisms are associated with platinum-based chemotherapy toxicity in Chinese patients with non-small cell lung cancer","volume":"37","author":"Chu","year":"2016","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"12411","DOI":"10.1073\/pnas.0805685105","article-title":"Polyubiquitination of proliferating cell nuclear antigen by HLTF and SHPRH prevents genomic instability from stalled replication forks","volume":"105","author":"Motegi","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"20786","DOI":"10.1073\/pnas.1011409107","article-title":"Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy","volume":"107","author":"Doles","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1158\/1078-0432.CCR-08-1227","article-title":"Polymerase eta mRNA expression predicts survival of non-small cell lung cancer patients treated with platinum-based chemotherapy","volume":"15","author":"Ceppi","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s13238-011-1098-y","article-title":"The Fanconi anemia pathway and DNA interstrand cross-link repair","volume":"2","author":"Su","year":"2011","journal-title":"Protein Cell"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1101\/gad.1196104","article-title":"ATR couples FANCD2 monoubiquitination to the DNA-damage response","volume":"18","author":"Andreassen","year":"2004","journal-title":"Genes Dev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3389\/fonc.2014.00368","article-title":"Fanconi anemia repair pathway dysfunction, a potential therapeutic target in lung cancer","volume":"4","author":"Duan","year":"2014","journal-title":"Front. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.chembiol.2011.08.014","article-title":"Selective and cell-active inhibitors of the USP1\/UAF1 deubiquitinase complex reverse cisplatin resistance in non-small cell lung cancer cells","volume":"18","author":"Chen","year":"2011","journal-title":"Chem. Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1476-4598-7-24","article-title":"Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin","volume":"7","author":"Burkitt","year":"2008","journal-title":"Mol. Cancer."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1158\/1535-7163.MCT-05-0493","article-title":"Chemosensitization to cisplatin by inhibitors of the Fanconi anemia\/BRCA pathway","volume":"5","author":"Chirnomas","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"ref_48","first-page":"e1","article-title":"SnapShot: Homologous Recombination in DNA Double-Strand Break Repair","volume":"142","author":"Mimitou","year":"2010","journal-title":"Cell"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"a017954","DOI":"10.1101\/cshperspect.a017954","article-title":"Regulation of DNA pairing in homologous recombination","volume":"6","author":"Daley","year":"2014","journal-title":"Cold Spring Harb Perspect. Biol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1534\/genetics.117.300285","article-title":"The role of Blm helicase in homologous recombination, gene conversion tract length, and recombination between diverged sequences in Drosophila melanogaster","volume":"207","author":"Ertl","year":"2017","journal-title":"Genetics"},{"key":"ref_51","first-page":"955","article-title":"Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review)","volume":"12","author":"Wang","year":"2004","journal-title":"Oncol. Rep."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12935-019-0910-2","article-title":"p53 sensitizes chemoresistant non-small cell lung cancer via elevation of reactive oxygen species and suppression of EGFR\/PI3K\/AKT signaling","volume":"19","author":"Zhang","year":"2019","journal-title":"Cancer Cell Int."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Hao, Q., Chen, Y., and Zhou, X. (2020). The janus face of p53-targeting ubiquitin ligases. Cells, 9.","DOI":"10.3390\/cells9071656"},{"key":"ref_54","first-page":"1574","article-title":"CDKN1A upregulation and cisplatin-pemetrexed resistance in non-small cell lung cancer cells","volume":"56","author":"Zamagni","year":"2020","journal-title":"Int. J. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/sj.bjc.6605418","article-title":"A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC","volume":"102","author":"Dean","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.3892\/ijo_00000464","article-title":"Increased expression of inhibitor of apoptosis proteins, survivin and XIAP in non-small cell lung carcinoma","volume":"35","author":"Krepela","year":"2009","journal-title":"Int. J. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/jcb.10440","article-title":"Apoptosis and lung cancer: A review","volume":"88","author":"Shivapurkar","year":"2003","journal-title":"J. Cell Biochem."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Yang, G., Wang, X.J., Huang, L.J., Zhou, Y.A., Tian, F., Zhao, J.B., and Zhang, Z.P. (2015). High ABCG4 expression is associated with poor prognosis in non-small-cell lung cancer patients treated with cisplatin-based chemotherapy. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0135576"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Prieto-Vila, M., Takahashi, R.-U., Usuba, W., Kohama, I., and Ochiya, T. (2017). Drug resistance driven by cancer stem cells and their niche. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18122574"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-981-13-7647-4_2","article-title":"ABC Family Transporters","volume":"1141","author":"Liu","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_61","first-page":"23","article-title":"Drug resistance in lung cancer","volume":"1","author":"Shanker","year":"2010","journal-title":"Lung Cancer"},{"key":"ref_62","first-page":"265","article-title":"Drug resistance mechanisms in non-small cell lung carcinoma","volume":"2","year":"2013","journal-title":"J. Cancer Res. Updates"},{"key":"ref_63","first-page":"4294","article-title":"MDIG promotes cisplatin resistance of lung adenocarcinoma by regulating ABC transporter expression via activation of the WNT\/\u03b2-catenin signaling pathway","volume":"18","author":"Wang","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.critrevonc.2015.05.012","article-title":"The role of ABC transporters in ovarian cancer progression and chemoresistance","volume":"96","author":"Ween","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12931-017-0537-6","article-title":"ABCB1 and ABCG2 drug transporters are differentially expressed in non-small cell lung cancers (NSCLC) and expression is modified by cisplatin treatment via altered Wnt signaling","volume":"18","author":"Vesel","year":"2017","journal-title":"Respir. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.critrevonc.2015.10.003","article-title":"Exploring miRNA based approaches in cancer diagnostics and therapeutics","volume":"98","author":"Mishra","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"4903152","DOI":"10.1155\/2019\/4903152","article-title":"MicroRNAs as Potential Biomarkers for Chemoresistance in Adenocarcinomas of the Esophagogastric Junction","volume":"2019","author":"Just","year":"2019","journal-title":"J. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.7150\/thno.22048","article-title":"A low microRNA-630 expression confers resistance to tyrosine kinase inhibitors in EGFR-mutated lung adenocarcinomas via miR-630\/YAP1\/ERK feedback loop","volume":"8","author":"Wu","year":"2018","journal-title":"Theranostics"},{"key":"ref_69","first-page":"1869","article-title":"MicroRNAs as regulators of cisplatin resistance in lung cancer","volume":"37","author":"Chen","year":"2015","journal-title":"CPB"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"13758","DOI":"10.18632\/oncotarget.24474","article-title":"MicroRNA-630 may confer favorable cisplatin-based chemotherapy and clinical outcomes in non-small cell lung cancer by targeting Bcl-2","volume":"9","author":"Chen","year":"2018","journal-title":"Oncotarget"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1158\/0008-5472.CAN-09-3112","article-title":"miR-181a and miR-630 regulate cisplatin-induced cancer cell death","volume":"70","author":"Galluzzi","year":"2010","journal-title":"Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jtho.2016.02.002","article-title":"Prognostic and predictive effect of TP53 mutations in patients with non-small cell lung cancer from adjuvant cisplatin-based therapy randomized trials: A LACE-bio pooled analysis","volume":"11","author":"Ma","year":"2016","journal-title":"J. Thorac Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1080\/01635581.2014.894101","article-title":"EGCG enhances the efficacy of cisplatin by downregulating hsa-miR-98-5p in NSCLC A549 cells","volume":"66","author":"Zhou","year":"2014","journal-title":"Nutr. Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/bjc.2014.157","article-title":"MiR-224 promotes the chemoresistance of human lung adenocarcinoma cells to cisplatin via regulating G1\/S transition and apoptosis by targeting p21(WAF1\/CIP1)","volume":"111","author":"Wang","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3892\/ijmm.2016.2513","article-title":"Downregulation of microRNA-196a enhances the sensitivity of non-small cell lung cancer cells to cisplatin treatment","volume":"37","author":"Li","year":"2016","journal-title":"Int. J. Mol. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.12669\/pjms.35.6.1322","article-title":"Genetic polymorphism of miRNA-196a and its target gene annexin-A1 expression based on ethnicity in Pakistani female breast cancer patients","volume":"35","author":"Rahim","year":"2019","journal-title":"Pak. J. Med. Sci."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"25076","DOI":"10.18632\/oncotarget.4725","article-title":"Annexin A1 is involved in the acquisition and maintenance of a stem cell-like\/aggressive phenotype in prostate cancer cells with acquired resistance to zoledronic acid","volume":"6","author":"Bizzarro","year":"2015","journal-title":"Oncotarget"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3892\/ol.2020.12402","article-title":"Annexin A1 is a potential biomarker of bone metastasis in small cell lung cancer","volume":"21","author":"Chen","year":"2021","journal-title":"Oncol. Lett."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Liu, X.H., Lu, K.H., Wang, K.M., Sun, M., Zhang, E.B., Yang, J.S., Yin, D.D., Liu, Z.L., Zhou, J., and Liu, Z.J. (2012). MicroRNA-196a promotes non-small cell lung cancer cell proliferation and invasion through targeting HOXA5. BMC Cancer, 12.","DOI":"10.1186\/1471-2407-12-348"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/cgt.2014.73","article-title":"miR-15b regulates cisplatin resistance and metastasis by targeting PEBP4 in human lung adenocarcinoma cells","volume":"22","author":"Zhao","year":"2015","journal-title":"Cancer Gene Ther."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Gkountakos, A., Sartori, G., Falcone, I., Piro, G., Ciuffreda, L., Carbone, C., Tortora, G., Scarpa, A., Bria, E., and Milella, M. (2019). PTEN in lung cancer: Dealing with the problem, building on new knowledge and turning the game around. Cancers, 11.","DOI":"10.3390\/cancers11081141"},{"key":"ref_82","first-page":"1333","article-title":"PTEN inhibits non-small cell lung cancer cell growth by promoting G0\/G1 arrest and cell apoptosis","volume":"17","author":"Liu","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"57832","DOI":"10.18632\/oncotarget.11068","article-title":"PTEN expression is a prognostic marker for patients with non-small cell lung cancer: A systematic review and meta-analysis of the literature","volume":"7","author":"Xiao","year":"2016","journal-title":"Oncotarget"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1002\/cbf.3568","article-title":"MicroRNA-92b acts as an oncogene by targeting PTEN\/AKT in NSCLC","volume":"38","author":"Guo","year":"2020","journal-title":"Cell Biochem. Funct."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11010-012-1443-3","article-title":"MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN","volume":"372","author":"Liu","year":"2013","journal-title":"Mol. Cell Biochem."},{"key":"ref_86","first-page":"4563","article-title":"miRNA-328 overexpression confers cisplatin resistance in non-small cell lung cancer via targeting of PTEN","volume":"18","author":"Wang","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"ref_87","first-page":"332","article-title":"Role of microRNAs in chemoresistance","volume":"3","author":"Magee","year":"2015","journal-title":"Ann. Transl. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/onc.2011.260","article-title":"miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222","volume":"31","author":"Acunzo","year":"2012","journal-title":"Oncogene"},{"key":"ref_89","first-page":"955","article-title":"Let-7c sensitizes acquired cisplatin-resistant A549 cells by targeting ABCC2 and Bcl-XL","volume":"68","author":"Zhan","year":"2013","journal-title":"Pharmazie"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Jiang, Z., Yin, J., Fu, W., Mo, Y., Pan, Y., Dai, L., Huang, H., Li, S., and Zhao, J. (2014). MiRNA 17 family regulates cisplatin-resistant and metastasis by targeting TGFbetaR2 in NSCLC. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0094639"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"24510","DOI":"10.18632\/oncotarget.8229","article-title":"miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Chatterjee, A., Chattopadhyay, D., and Chakrabarti, G. (2014). miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin1 expression. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0095716"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.3389\/fonc.2019.01372","article-title":"A strong decrease in TIMP3 expression mediated by the presence of miR-17 and 20a enables extracellular matrix remodeling in the NSCLC lesion surroundings","volume":"9","author":"Czarnecka","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3389\/fonc.2020.00643","article-title":"MiR-200b Inhibits Tumor Growth and Chemoresistance via Targeting p70S6K1 in Lung Cancer","volume":"10","author":"Jin","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Chan, Y.T., Lin, Y.C., Lin, R.J., Kuo, H.H., Thang, W.C., Chiu, K.P., and Yu, A.L. (2013). Concordant and discordant regulation of target genes by miR-31 and its isoforms. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0058169"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1042\/BCJ20160759","article-title":"Molecular mechanisms of Dicer: Endonuclease and enzymatic activity","volume":"474","author":"Song","year":"2017","journal-title":"Biochem. J."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/s41598-018-19339-5","article-title":"Exosome-mediated breast cancer chemoresistance via miR-155 transfer","volume":"8","author":"Santos","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"5986","DOI":"10.7150\/thno.26650","article-title":"Chemoresistance transmission via exosome-mediated EphA2 transfer in pancreatic cancer","volume":"8","author":"Fan","year":"2018","journal-title":"Theranostics"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"E3355","DOI":"10.1073\/pnas.1504630112","article-title":"A set of NF-\u03baB-regulated microRNAs induces acquired TRAIL resistance in lung cancer","volume":"112","author":"Jeon","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ccr.2009.10.014","article-title":"miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation","volume":"16","author":"Garofalo","year":"2009","journal-title":"Cancer Cell."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1596004","DOI":"10.1080\/2162402X.2019.1596004","article-title":"Interaction of tumor-associated macrophages and cancer chemotherapy","volume":"8","author":"Larionova","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Chen, S.-H., and Chang, J.-Y. (2019). New insights into mechanisms of cisplatin resistance: From tumor cell to microenvironment. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20174136"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13046-019-1166-3","article-title":"Cisplatin resistant lung cancer cells promoted M2 polarization of tumor-associated macrophages via the Src\/CD155\/MIF functional pathway","volume":"38","author":"Huang","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e652035","DOI":"10.1155\/2015\/652035","article-title":"Leukocytes: The double-edged sword in fibrosis","volume":"2015","author":"Kryczka","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Ashrafizadeh, M., Zarrabi, A., Hushmandi, K., Kalantari, M., Mohammadinejad, R., Javaheri, T., and Sethi, G. (2020). Association of the Epithelial-Mesenchymal transition (EMT) with cisplatin resistance. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21114002"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.canlet.2019.12.024","article-title":"Cisplatin-stimulated macrophages promote ovarian cancer migration via the CCL20-CCR6 axis","volume":"472","author":"Liu","year":"2020","journal-title":"Cancer Lett."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Kirshberg, S., Izhar, U., Amir, G., Demma, J., Vernea, F., Beider, K., Shlomai, Z., Wald, H., Zamir, G., and Shapira, O.M. (2011). Involvement of CCR6\/CCL20\/IL-17 axis in NSCLC disease progression. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0024856"},{"key":"ref_108","first-page":"183","article-title":"Relationship of metabolic alterations and PD-L1 expression in cisplatin resistant lung cancer","volume":"6","author":"Wangpaichitr","year":"2017","journal-title":"Cell Dev. Biol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1111\/cas.13072","article-title":"Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy","volume":"107","author":"Zhang","year":"2016","journal-title":"Cancer Sci."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.canlet.2019.08.005","article-title":"Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer","volume":"464","author":"Fournel","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"83986","DOI":"10.18632\/oncotarget.20233","article-title":"Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer","volume":"8","author":"Lin","year":"2017","journal-title":"Oncotarget"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/mt.2015.10","article-title":"The clinical relevance of the miR-197\/CKS1B\/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer","volume":"23","author":"Fujita","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.currproblcancer.2016.12.002","article-title":"Targeting the PD-1\/PD-L1 axis in non-small cell lung cancer","volume":"41","author":"Kumar","year":"2017","journal-title":"Curr. Probl. Cancer."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.critrevonc.2016.03.007","article-title":"Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1\/PD-L1 agents: A meta-analysis","volume":"101","year":"2016","journal-title":"Crit Rev. Oncol. Hematol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2014.58.3708","article-title":"Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer","volume":"33","author":"Gettinger","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.3389\/fonc.2019.01215","article-title":"The metabolic landscape of lung cancer: New insights in a disturbed glucose metabolism","volume":"9","author":"Vanhove","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","article-title":"The warburg effect: How does it benefit cancer cells?","volume":"41","author":"Liberti","year":"2016","journal-title":"Trends Biochem. Sci."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/bph.13422","article-title":"The Warburg effect and drug resistance","volume":"173","author":"Bhattacharya","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e15938","DOI":"10.7554\/eLife.15938","article-title":"Partners in the Warburg effect","volume":"5","author":"Rabinowitz","year":"2016","journal-title":"eLife"},{"key":"ref_121","unstructured":"(2021, April 14). Home\u2014GEO\u2014NCBI, Available online: https:\/\/www.ncbi.nlm.nih.gov\/geo\/."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Makondi, P.T., Chu, C.-M., Wei, P.-L., and Chang, Y.-J. (2017). Prediction of novel target genes and pathways involved in irinotecan-resistant colorectal cancer. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0180616"},{"key":"ref_123","unstructured":"(2021, April 14). STRING: Functional Protein Association Networks. Available online: https:\/\/string-db.org\/."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s13059-019-1758-4","article-title":"Cytoscape automation: Empowering workflow-based network analysis","volume":"20","author":"Otasek","year":"2019","journal-title":"Genome Biol."},{"key":"ref_125","unstructured":"(2021, April 14). DAVID Functional Annotation Bioinformatics Microarray Analysis, Available online: https:\/\/david.ncifcrf.gov\/."},{"key":"ref_126","unstructured":"(2021, April 14). KEGG PATHWAY Database. Available online: https:\/\/www.kegg.jp\/kegg\/pathway.html."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/16\/8885\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:46:29Z","timestamp":1760165189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/16\/8885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,18]]},"references-count":126,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["ijms22168885"],"URL":"https:\/\/doi.org\/10.3390\/ijms22168885","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,18]]}}}